Teva Pharmaceutical Indus...

NYSE: TEVA · Real-Time Price · USD
17.57
0.03 (0.17%)
At close: Aug 15, 2025, 9:59 AM

Teva Pharmaceutical Industries Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
4.18B 3.89B 4.23B 4.33B 4.16B 3.83B 4.46B 3.85B 3.88B 3.66B 3.88B 3.6B 3.79B 3.66B 4.1B 3.89B 3.91B 3.98B
Cost of Revenue
2.07B 2.01B 2.11B 2.18B 2.14B 2.05B 2.04B 2B 2.08B 2.08B 2.11B 1.93B 1.99B 1.92B 2.05B 2.09B 2.04B 2.1B
Gross Profit
2.1B 1.88B 2.12B 2.15B 2.02B 1.78B 2.42B 1.85B 1.8B 1.58B 1.77B 1.67B 1.79B 1.74B 2.05B 1.79B 1.87B 1.88B
Operating Income
455M 519M -29M -51M 814M 656M 722M 355M -646M -13M 743M 672M -949M -713M 78M 623M 582M 434M
Interest Income
n/a n/a n/a n/a n/a n/a n/a n/a 226M n/a 227M n/a n/a n/a n/a n/a n/a n/a
Pretax Income
203M 294M -247M -324M -246M -467M 473M 75M -914M -272M -1.1B 166M -1.16B -971M -175M 382M 308M 144M
Net Income
282M 214M -217M -437M -845M -139M 429M 80M -863M -220M -1.22B 56M -232M -955M -159M 292M 207M 77M
Selling & General & Admin
959M 919M 952M 924M 939M 886M 902M 844M 910M 842M 838M 822M 907M 880M 908M 888M 857M 875M
Research & Development
244M 247M 248M 240M 269M 242M 227M 253M 240M 234M 210M 175M 228M 225M 244M 222M 248M 254M
Other Expenses
n/a 192M 949M n/a 1M n/a n/a 9M n/a 520M n/a 1M n/a 1.35B n/a n/a n/a 5M
Operating Expenses
1.2B 1.36B 2.15B 1.16B 1.21B 1.13B 1.13B 1.1B 1.15B 1.6B 1.05B 997M 1.14B 2.45B 1.15B 1.11B 1.1B 1.13B
Interest Expense
n/a 225M 239M 272M 241M 250M 260M 280M 268M 260M 245M 252M 211M 258M 180M 241M 240M 290M
Selling & Marketing Expenses
654M 622M 650M 626M 656M 608M 610M 576M 603M 546M 549M 539M 594M 584M 632M 597M 615M 585M
Cost & Expenses
3.28B 3.37B 4.26B 3.35B 3.35B 3.18B 3.17B 3.1B 3.23B 3.67B 3.16B 2.92B 3.13B 4.37B 3.2B 3.2B 3.14B 3.23B
Income Tax Expense
-79M 74M 28M 69M 630M -52M 41M -12M -16M -19M 154M 107M -900M 2M -24M 76M 98M 62M
Shares Outstanding (Basic)
1.15B 1.14B 1.13B 1.13B 1.13B 1.12B 1.12B 1.12B 1.12B 1.11B 1.11B 1.11B 1.11B 1.11B 1.1B 1.1B 1.1B 1.1B
Shares Outstanding (Diluted)
1.16B 1.16B 1.13B 1.13B 1.13B 1.12B 1.14B 1.14B 1.12B 1.11B 1.11B 1.12B 1.11B 1.11B 1.1B 1.11B 1.11B 1.11B
EPS (Basic)
0.25 0.19 -0.19 -0.39 -0.75 -0.12 0.41 0.07 -0.77 -0.2 -1.1 0.05 -0.21 -0.86 -0.14 0.26 0.19 0.07
EPS (Diluted)
0.24 0.18 -0.19 -0.39 -0.75 -0.12 0.41 0.07 -0.77 -0.2 -1.1 0.05 -0.21 -0.86 -0.14 0.26 0.19 0.07
EBITDA
455M 763M 261M 210M 254M 45M 1.52B 1.04B -382M 292M -488M 994M -592M -390M 1.16B 1.04B 582M 810M
EBIT
n/a 519M -8M -52M -5M -227M 694M 344M -655M -12M -892M 418M -950M -713M -89M 623M 609M 434M
Depreciation & Amortization
n/a 244M 269M 259M 259M 272M 266M 283M 300M 304M 306M 321M 358M 323M 320M 329M 307M 376M